These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 23383319)

  • 1. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.
    Maasoumy B; Port K; Markova AA; Serrano BC; Rogalska-Taranta M; Sollik L; Mix C; Kirschner J; Manns MP; Wedemeyer H; Cornberg M
    PLoS One; 2013; 8(2):e55285. PubMed ID: 23383319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
    Cooper C; Lester R; Thorlund K; Druyts E; El Khoury AC; Yaya S; Mills EJ
    QJM; 2013 Feb; 106(2):153-63. PubMed ID: 23159839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Sitole M; Silva M; Spooner L; Comee MK; Malloy M
    Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.
    Ioniţă-Radu F; Raşcanu A; Cheiab B
    Rom J Intern Med; 2011; 49(2):99-104. PubMed ID: 22303600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    Arends JE; van der Meer JT; Posthouwer D; Kortmann W; Brinkman K; van Assen S; Smit C; van der Valk M; van der Ende M; Schinkel J; Reiss P; Richter C; Hoepelman AI; ;
    Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
    Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
    PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease inhibitors: silver bullets for chronic hepatitis C infection?
    Alkhouri N; Zein NN
    Cleve Clin J Med; 2012 Mar; 79(3):213-22. PubMed ID: 22383557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
    Wehmeyer MH; Eißing F; Jordan S; Röder C; Hennigs A; Degen O; Hüfner A; Hertling S; Schmiedel S; Sterneck M; van Lunzen J; Lohse AW; Schulze zur Wiesch J; Lüth S
    BMC Gastroenterol; 2014 May; 14():87. PubMed ID: 24884400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis.
    Manzano-Robleda Mdel C; Ornelas-Arroyo V; Barrientos-Gutiérrez T; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2015; 14(1):46-57. PubMed ID: 25536641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Shiffman ML; Esteban R
    Liver Int; 2012 Feb; 32 Suppl 1():54-60. PubMed ID: 22212573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.